胃癌化疗后肿瘤相关性贫血发生率及促红细胞生成素联用铁剂干预的临床效果  

THE INCIDENCE OF TUMOR-ASSOCIATED ANEMIA AFTER GASTRIC CANCER CHEMOTHERAPY AND THE CLINICAL EFFECT OF EPO COMBINED WITH IRON INTERVENTION

作　　者：李春香 刘地发 徐杰 Li Chunxiang;Liu Difa;Xu Jie(Department of Oncology ,The People's Hospital of Haian ,Nantong University,Haian 226600,China)

机构地区：[1]南通大学附属海安医院肿瘤科

出　　处：《中国煤炭工业医学杂志》2018年第6期633-636,共4页Chinese Journal of Coal Industry Medicine

基　　金：江苏省卫生厅重点科研项目(编号:K201109)

摘　　要：目的统计胃癌化疗后肿瘤相关性贫血发生率,并观察促红细胞生成素(EPO)联用铁剂干预的临床效果。方法我院2015年1月-2017年12月收治249例胃癌患者,观察其化疗后肿瘤相关性贫血及贫血分级。将发生贫血者随机分为观察组、对照组,均给予铁剂干预,观察组加用EPO,比较二组患者干预效果、血常规指标变化及不良反应发生情况,分析EPO联用铁剂干预的临床效果与安全性。结果249例胃癌患者中,共检出肿瘤相关性贫血86例,发生率为34.54%。观察组干预总有效率为95.35%,高于对照组的76.74%,差异有统计学意义(P<0.05)。二组患者干预后Hb、Hct、RBC均较干预前升高,观察组干预后Hb、Hct、RBC高于对照组,差异有统计学意义(P<0.05)。观察组、对照组干预期间不良反应发生率分别为13.95%、11.63%,组间比较差异无统计学意义(P>0.05)。结论胃癌化疗后肿瘤相关性贫血发生率较高,强调贫血的早期筛查并给予EPO联合铁剂干预,能够有效控制贫血进展,保证化疗效果。Objective To count the incidence of tumor-associated anemia after gastric cancer chemotherapy, and to observe the clinical effect of erythropoietin (EPO)combined with iron intervention.Methods The clinical data of 249patients with gastric cancer in author's hospital from January 2015to December 2017were analyzed.The tumor-related anemia and anemia grade after chemotherapy were observed.The anemia patients were randomly divided into observation group and control group.AlI patients were treated with iron intervention,while the observation group was treated with EPO.The intervention effect,changes of blood routine index and adverse reactions were compared between the two groups.Clinical effects and safety of the EPO combined with iron intervention were analyzed.Results Of the 249patients with gastric cancer,86cases of tumor-associated anemia were detected,the incidence rate was 34.54%.The total effective rate of the observation group was 95.35%,which was higher than that {76.74%)of the control group (P<0.05).The Hb,Hct and RBC of the two groups were higher than those before the intervention.The Hb,Hct and RBC of the observation group were higher than those of the control group (P<0.05).The incidence of adverse reactions during the intervention in the observation group and the control group were 13.95%and 11.63%,respectively.There was no significant difference between the two groups (P>0.05).Conclusion The incidence of tumor-associated anemia after gastric cancer chemotherapy is high.Emphasis on early screening of anemia and intervention with EPO combined with iron can effectively control the progression of anemia and ensure the effect of chemotherapy.

关 键 词：胃癌 肿瘤相关性贫血 促红细胞生成素 铁剂 

分 类 号：R730.5[医药卫生—肿瘤]